United States Rystiggo Drug Market: Market Size & Forecast 2026

Rystiggo (rozanolixizumab) is an anti-FcRn monoclonal antibody administered via subcutaneous injection, designed to reduce pathogenic IgG autoantibodies responsible for several autoimmune and neurological conditions. The drug received FDA approval for myasthenia gravis in 2023 and has since expanded into additional indications, driving rapid uptake in the U.S. specialty pharmaceutical sector. The domestic market reached roughly $311 million in 2025 and is estimated at $334 million in 2026, with projections extending to approximately $539 million by 2031.

• •Market valued at $334 million in 2026, up from $311 million in 2025, on track to reach $539 million by 2031 at a 7.85% CAGR
• •Targets FcRn-mediated IgG recycling to treat autoimmune and neurological conditions including myasthenia gravis and immune thrombocytopenia
• •U.S. represents the largest national market for rozanolixizumab globally, supported by FDA approvals and a mature specialty drug reimbursement framework

The expanding clinical label for Rystiggo is the single largest growth lever, as each new FDA-approved indication unlocks a substantially larger treatable patient population. Rising national prevalence of autoimmune disorders, coupled with increasing physician familiarity with FcRn-targeted mechanisms, is driving prescription adoption in neurology, hematology, and rheumatology settings. Favorable third-party reimbursement for orphan and specialty-designated biologics further reduces out-of-pocket barriers and sustains patient adherence.

• •Sequential FDA label expansions into additional autoimmune indications multiply the addressable patient pool beyond the initial approved condition
• •High prevalence of IgG-mediated autoimmune diseases in the U.S. adult population provides a durable, long-term demand base
• •Specialty pharmacy and infusion networks are well-established for biologic delivery, enabling efficient market penetration as indications grow

Within the United States, the market is segmented primarily by therapeutic indication, myasthenia gravis, immune thrombocytopenia, and other IgG-driven autoimmune disorders, with each segment expanding as clinical data accumulates. Distribution is heavily concentrated in major metropolitan areas with high density of academic medical centers and specialized neurology and hematology practices. The Northeast and West Coast regions lead in early adoption rates, driven by higher concentration of teaching hospitals and clinical trial infrastructure, while the South and Midwest are experiencing accelerating uptake as community-based specialists gain experience with the therapy.

• •Myasthenia gravis represents the largest current indication segment, with immune thrombocytopenia and pipeline indications showing the fastest relative growth
• •Academic medical centers and large integrated delivery networks are primary prescription hubs, followed by community specialty practices in mature markets
• •Geographically, the U.S. market is anchored in the Northeast and Pacific West, with the South and Midwest representing the highest incremental growth opportunity

Who are the notable companies in the industry?

The United States Rystiggo Drug Market is defined by a concentrated competitive structure, with UCB S.A. as the established operator in the anti-FcRn therapeutic space. The drug has secured a clear clinical position in generalized myasthenia gravis, offering coverage for both anti-acetylcholine receptor and anti-muscle-specific kinase antibody-positive disease, which has underpinned steady physician uptake as specialists have grown more comfortable with repeat-cycle use. Production relies on mammalian cell culture systems, predominantly Chinese hamster ovary cell lines, requiring highly specialized upstream and downstream processing infrastructure concentrated at a limited number of large-scale biologic facilities with established FDA inspection histories. This manufacturing complexity reinforces the supply-chain concentration already evident in the market's participant structure. Near-term competitive pressure is emerging after the April 2025 approval of IMAAVY, though Rystiggo retains orphan drug exclusivity through June 26, 2030, which protects early forecast-period pricing and limits biosimilar risk during the market's projected growth from USD 369.37 million in 2026 to USD 538.97 million by 2031 at a 7.85% CAGR.

• •Highly consolidated market with a limited number of active producers in the anti-Fcrn biologic segment, supported by high barriers to entry including complex R&D and stringent regulatory pathways
• •Biologics are manufactured via mammalian cell culture using CHO expression systems, requiring large-scale upstream bioreactor capacity and sophisticated downstream purification infrastructure
• •Manufacturing and finished-goods capacity is geographically concentrated at established GMP-compliant facilities with extensive FDA inspection and approval track records

What are the recent trends and outlook?

The market is positioned for sustained multi-year expansion, with the 7.85% CAGR through 2031 underpinned by continued indication diversification and long-term autoimmune disease management in real-world settings. Emerging pipeline data for additional IgG-mediated conditions could meaningfully extend the peak-sales horizon beyond current projections. Competitive dynamics in the broader FcRn inhibitor class may influence pricing pressure and formulary positioning over time, though early-stage differentiation through dosing profiles and safety data is expected to preserve market access for existing products.

• •Projected trajectory takes the market from $334 million in 2026 to $539 million by 2031, representing a roughly 61% cumulative expansion over the five-year period
• •Pipeline development for additional autoimmune and neurological indications could substantially expand the label beyond the current approved indications
• •Long-acting subcutaneous formulation development and real-world evidence generation are expected to reinforce clinical value propositions and payer coverage confidence